Mepolizumab
Brand name: Nucala
Rank #174 of 500 drugs by total cost
$90.1M
Total Cost
20,798
Total Claims
$90.1M
Total Cost
961
Prescribers
$4,331
Cost per Claim
285
Beneficiaries
21,341
30-Day Fills
$94K
Avg Cost/Provider
22
Avg Claims/Provider
About Mepolizumab
Mepolizumab (sold as Nucala) was prescribed 20,798 times by 961 Medicare Part D providers in 2023, costing the program $90.1M. At $4,331 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 171 | Latanoprost (Latanoprost) | $92.3M | 4,388,601 |
| 172 | Ribociclib Succinate (Kisqali) | $90.3M | 5,978 |
| 173 | Lacosamide (Lacosamide) | $90.1M | 300,038 |
| 174 | Mepolizumab (Nucala) | $90.1M | 20,798 |
| 175 | Finerenone (Kerendia) | $89.5M | 93,151 |
| 176 | Ixazomib Citrate (Ninlaro) | $89.0M | 6,901 |
| 177 | Lamotrigine (Lamotrigine) | $89.0M | 1,603,798 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology